No abstract

Although sensitivity was good in one included study, considering the poor specificity and the limited data available in the literature, we cannot recommend routine use of F-florbetapir PET in clinical practice to predict the progression from MCI to ADD.Because of the poor sensitivity and specificity, limited number of included participants, and the limited data available in the literature, we cannot recommend its routine use in clinical practice to predict the progression from MCI to any form of dementia.Because of the high financial costs ofF-florbetapir, clearly demonstrating the DTA and standardising the process of this modality are important prior to its wider use.

Although we were able to calculate one estimation of DTA in, especially, the prediction of progression from MCI to ADD at four years follow-up, the small number of participants implies imprecision of sensitivity and specificity estimates. We cannot make any recommendation regarding the routine use of F-florbetaben in clinical practice based on one single study with 45 participants.F-florbetaben has high financial costs, therefore, clearly demonstrating its DTA and standardising the process of the F-florbetaben modality are important prior to its wider use.